WO2003095425A1 - Derives de cyanopyrrolidine - Google Patents
Derives de cyanopyrrolidine Download PDFInfo
- Publication number
- WO2003095425A1 WO2003095425A1 PCT/JP2003/005813 JP0305813W WO03095425A1 WO 2003095425 A1 WO2003095425 A1 WO 2003095425A1 JP 0305813 W JP0305813 W JP 0305813W WO 03095425 A1 WO03095425 A1 WO 03095425A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- group
- carbon atoms
- substituted
- atom
- hydrogen atom
- Prior art date
Links
- QJRYYOWARFCJQZ-UHFFFAOYSA-N pyrrolidine-1-carbonitrile Chemical class N#CN1CCCC1 QJRYYOWARFCJQZ-UHFFFAOYSA-N 0.000 title claims abstract description 17
- 125000004432 carbon atom Chemical group C* 0.000 claims abstract description 106
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 51
- 125000003277 amino group Chemical group 0.000 claims abstract description 43
- 125000005843 halogen group Chemical group 0.000 claims abstract description 35
- 150000003839 salts Chemical class 0.000 claims abstract description 31
- 125000004122 cyclic group Chemical group 0.000 claims abstract description 15
- 239000001257 hydrogen Substances 0.000 claims abstract description 13
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract description 13
- 125000002252 acyl group Chemical group 0.000 claims abstract description 12
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims abstract description 9
- 150000001413 amino acids Chemical class 0.000 claims abstract description 7
- 125000004433 nitrogen atom Chemical group N* 0.000 claims abstract description 7
- 125000005129 aryl carbonyl group Chemical group 0.000 claims abstract description 6
- 229910052757 nitrogen Inorganic materials 0.000 claims abstract description 6
- 229910052717 sulfur Chemical group 0.000 claims abstract description 3
- -1 guanidyl group Chemical group 0.000 claims description 76
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 50
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 41
- 102000016622 Dipeptidyl Peptidase 4 Human genes 0.000 claims description 22
- 101000930822 Giardia intestinalis Dipeptidyl-peptidase 4 Proteins 0.000 claims description 22
- 125000003545 alkoxy group Chemical group 0.000 claims description 22
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 22
- 239000003814 drug Substances 0.000 claims description 19
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 17
- 229910052799 carbon Inorganic materials 0.000 claims description 15
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 14
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims description 13
- 230000002401 inhibitory effect Effects 0.000 claims description 13
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 claims description 11
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 11
- 125000004076 pyridyl group Chemical group 0.000 claims description 11
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 10
- 125000006165 cyclic alkyl group Chemical group 0.000 claims description 9
- 125000004414 alkyl thio group Chemical group 0.000 claims description 8
- 150000001602 bicycloalkyls Chemical group 0.000 claims description 8
- 150000001721 carbon Chemical group 0.000 claims description 8
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 8
- 201000010099 disease Diseases 0.000 claims description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 8
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 7
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 claims description 7
- 125000002883 imidazolyl group Chemical group 0.000 claims description 7
- 125000001041 indolyl group Chemical group 0.000 claims description 7
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 claims description 7
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 7
- 125000003396 thiol group Chemical group [H]S* 0.000 claims description 7
- 125000003342 alkenyl group Chemical group 0.000 claims description 6
- 208000026278 immune system disease Diseases 0.000 claims description 6
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 6
- 206010012601 diabetes mellitus Diseases 0.000 claims description 5
- 229910052740 iodine Inorganic materials 0.000 claims description 5
- 125000004430 oxygen atom Chemical group O* 0.000 claims description 5
- 230000001668 ameliorated effect Effects 0.000 claims description 4
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 4
- 125000004434 sulfur atom Chemical group 0.000 claims description 3
- 239000004480 active ingredient Substances 0.000 claims description 2
- 125000004429 atom Chemical group 0.000 claims 2
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical group O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 claims 1
- YZCKVEUIGOORGS-IGMARMGPSA-N Protium Chemical compound [1H] YZCKVEUIGOORGS-IGMARMGPSA-N 0.000 claims 1
- 239000004020 conductor Substances 0.000 claims 1
- 150000002431 hydrogen Chemical group 0.000 abstract description 5
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 abstract 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 abstract 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 239000001301 oxygen Substances 0.000 abstract 1
- 239000011593 sulfur Chemical group 0.000 abstract 1
- 238000006243 chemical reaction Methods 0.000 description 112
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 89
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 86
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 85
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 84
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 68
- 150000001875 compounds Chemical class 0.000 description 60
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 54
- 239000002904 solvent Substances 0.000 description 46
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 45
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 42
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 36
- 238000000034 method Methods 0.000 description 34
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 31
- 239000000243 solution Substances 0.000 description 29
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 28
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 25
- 230000015572 biosynthetic process Effects 0.000 description 23
- 238000003786 synthesis reaction Methods 0.000 description 23
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 22
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 21
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 19
- 239000000203 mixture Substances 0.000 description 19
- 230000002829 reductive effect Effects 0.000 description 19
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 18
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 16
- 150000001412 amines Chemical class 0.000 description 15
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 15
- 239000011734 sodium Substances 0.000 description 15
- 238000001816 cooling Methods 0.000 description 14
- 150000007529 inorganic bases Chemical class 0.000 description 13
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 12
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 12
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 12
- 238000007112 amidation reaction Methods 0.000 description 12
- 238000012360 testing method Methods 0.000 description 12
- 210000004369 blood Anatomy 0.000 description 11
- 239000008280 blood Substances 0.000 description 11
- 239000007810 chemical reaction solvent Substances 0.000 description 11
- 239000000843 powder Substances 0.000 description 11
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 10
- 239000002253 acid Substances 0.000 description 10
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
- 230000005764 inhibitory process Effects 0.000 description 9
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 9
- FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 9
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 8
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 8
- 230000009435 amidation Effects 0.000 description 8
- 229910021529 ammonia Inorganic materials 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 229910000027 potassium carbonate Inorganic materials 0.000 description 8
- 125000006239 protecting group Chemical group 0.000 description 8
- 238000010898 silica gel chromatography Methods 0.000 description 8
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 7
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 7
- 125000000392 cycloalkenyl group Chemical group 0.000 description 7
- 239000008103 glucose Substances 0.000 description 7
- OTWVFHZMWFGHSJ-UHFFFAOYSA-N 1-fluoropyrrolidine Chemical compound FN1CCCC1 OTWVFHZMWFGHSJ-UHFFFAOYSA-N 0.000 description 6
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- 235000008733 Citrus aurantifolia Nutrition 0.000 description 6
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 235000011941 Tilia x europaea Nutrition 0.000 description 6
- 239000007864 aqueous solution Substances 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 125000000031 ethylamino group Chemical group [H]C([H])([H])C([H])([H])N([H])[*] 0.000 description 6
- 238000001914 filtration Methods 0.000 description 6
- 125000001153 fluoro group Chemical group F* 0.000 description 6
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 6
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 6
- 239000004571 lime Substances 0.000 description 6
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 6
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 5
- 108010067722 Dipeptidyl Peptidase 4 Proteins 0.000 description 5
- 102100025012 Dipeptidyl peptidase 4 Human genes 0.000 description 5
- 235000001014 amino acid Nutrition 0.000 description 5
- 229940024606 amino acid Drugs 0.000 description 5
- 229910052801 chlorine Inorganic materials 0.000 description 5
- 125000001309 chloro group Chemical group Cl* 0.000 description 5
- 239000002274 desiccant Substances 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 150000002148 esters Chemical class 0.000 description 5
- 239000002994 raw material Substances 0.000 description 5
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 4
- YYROPELSRYBVMQ-UHFFFAOYSA-N 4-toluenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 description 4
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 4
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 4
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 4
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- 235000011054 acetic acid Nutrition 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 125000004093 cyano group Chemical group *C#N 0.000 description 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 4
- 229910052731 fluorine Inorganic materials 0.000 description 4
- 229940098779 methanesulfonic acid Drugs 0.000 description 4
- 239000012044 organic layer Substances 0.000 description 4
- 239000012074 organic phase Substances 0.000 description 4
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 4
- VYPDUQYOLCLEGS-UHFFFAOYSA-M sodium;2-ethylhexanoate Chemical compound [Na+].CCCCC(CC)C([O-])=O VYPDUQYOLCLEGS-UHFFFAOYSA-M 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- RWRDLPDLKQPQOW-UHFFFAOYSA-N tetrahydropyrrole Natural products C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 4
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 4
- WORJRXHJTUTINR-UHFFFAOYSA-N 1,4-dioxane;hydron;chloride Chemical compound Cl.C1COCCO1 WORJRXHJTUTINR-UHFFFAOYSA-N 0.000 description 3
- CZMRCDWAGMRECN-UHFFFAOYSA-N 2-{[3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]oxy}-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound OCC1OC(CO)(OC2OC(CO)C(O)C(O)C2O)C(O)C1O CZMRCDWAGMRECN-UHFFFAOYSA-N 0.000 description 3
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 3
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 description 3
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- 241000725303 Human immunodeficiency virus Species 0.000 description 3
- 102000004877 Insulin Human genes 0.000 description 3
- 108090001061 Insulin Proteins 0.000 description 3
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 3
- 150000008065 acid anhydrides Chemical class 0.000 description 3
- 239000012190 activator Substances 0.000 description 3
- 235000011114 ammonium hydroxide Nutrition 0.000 description 3
- 125000003118 aryl group Chemical group 0.000 description 3
- WGQKYBSKWIADBV-UHFFFAOYSA-N benzylamine Chemical compound NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 238000005893 bromination reaction Methods 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
- AOGYCOYQMAVAFD-UHFFFAOYSA-M carbonochloridate Chemical compound [O-]C(Cl)=O AOGYCOYQMAVAFD-UHFFFAOYSA-M 0.000 description 3
- 239000003054 catalyst Substances 0.000 description 3
- 238000005660 chlorination reaction Methods 0.000 description 3
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 3
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 3
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 3
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 3
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 3
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 3
- MKRTXPORKIRPDG-UHFFFAOYSA-N diphenylphosphoryl azide Chemical compound C=1C=CC=CC=1P(=O)(N=[N+]=[N-])C1=CC=CC=C1 MKRTXPORKIRPDG-UHFFFAOYSA-N 0.000 description 3
- 229940125396 insulin Drugs 0.000 description 3
- 238000006192 iodination reaction Methods 0.000 description 3
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- 125000005948 methanesulfonyloxy group Chemical group 0.000 description 3
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 206010039073 rheumatoid arthritis Diseases 0.000 description 3
- 235000009518 sodium iodide Nutrition 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- OBETXYAYXDNJHR-SSDOTTSWSA-M (2r)-2-ethylhexanoate Chemical compound CCCC[C@@H](CC)C([O-])=O OBETXYAYXDNJHR-SSDOTTSWSA-M 0.000 description 2
- QYCGBAJADAGLLK-UHFFFAOYSA-N 1-(cyclohepten-1-yl)cycloheptene Chemical group C1CCCCC=C1C1=CCCCCC1 QYCGBAJADAGLLK-UHFFFAOYSA-N 0.000 description 2
- VSIYJQNFMOOGCU-UHFFFAOYSA-N 1-(cyclohexen-1-yl)cyclohexene Chemical group C1CCCC(C=2CCCCC=2)=C1 VSIYJQNFMOOGCU-UHFFFAOYSA-N 0.000 description 2
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 2
- LNWWQYYLZVZXKS-UHFFFAOYSA-N 1-pyrrolidin-1-ylethanone Chemical compound CC(=O)N1CCCC1 LNWWQYYLZVZXKS-UHFFFAOYSA-N 0.000 description 2
- WGTASENVNYJZBK-UHFFFAOYSA-N 3,4,5-trimethoxyamphetamine Chemical group COC1=CC(CC(C)N)=CC(OC)=C1OC WGTASENVNYJZBK-UHFFFAOYSA-N 0.000 description 2
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 2
- CDDGNGVFPQRJJM-UHFFFAOYSA-N 3-fluoropyrrolidine Chemical compound FC1CCNC1 CDDGNGVFPQRJJM-UHFFFAOYSA-N 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 108010016626 Dipeptides Proteins 0.000 description 2
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 2
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 102000035195 Peptidases Human genes 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 2
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 2
- 208000004403 Prostatic Hyperplasia Diseases 0.000 description 2
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 2
- YRKCREAYFQTBPV-UHFFFAOYSA-N acetylacetone Chemical compound CC(=O)CC(C)=O YRKCREAYFQTBPV-UHFFFAOYSA-N 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 150000001263 acyl chlorides Chemical class 0.000 description 2
- 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 description 2
- 235000004279 alanine Nutrition 0.000 description 2
- OBETXYAYXDNJHR-UHFFFAOYSA-N alpha-ethylcaproic acid Natural products CCCCC(CC)C(O)=O OBETXYAYXDNJHR-UHFFFAOYSA-N 0.000 description 2
- 150000001408 amides Chemical class 0.000 description 2
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 description 2
- 150000005350 bicyclononyls Chemical group 0.000 description 2
- 230000031709 bromination Effects 0.000 description 2
- XJHCXCQVJFPJIK-UHFFFAOYSA-M caesium fluoride Chemical compound [F-].[Cs+] XJHCXCQVJFPJIK-UHFFFAOYSA-M 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 125000001047 cyclobutenyl group Chemical group C1(=CCC1)* 0.000 description 2
- 125000004850 cyclobutylmethyl group Chemical group C1(CCC1)C* 0.000 description 2
- 125000001162 cycloheptenyl group Chemical group C1(=CCCCCC1)* 0.000 description 2
- WVIIMZNLDWSIRH-UHFFFAOYSA-N cyclohexylcyclohexane Chemical group C1CCCCC1C1CCCCC1 WVIIMZNLDWSIRH-UHFFFAOYSA-N 0.000 description 2
- 125000000522 cyclooctenyl group Chemical group C1(=CCCCCCC1)* 0.000 description 2
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 2
- 238000006297 dehydration reaction Methods 0.000 description 2
- 238000010511 deprotection reaction Methods 0.000 description 2
- 238000007865 diluting Methods 0.000 description 2
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 210000003038 endothelium Anatomy 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 238000003682 fluorination reaction Methods 0.000 description 2
- 230000004153 glucose metabolism Effects 0.000 description 2
- 229960002897 heparin Drugs 0.000 description 2
- 229920000669 heparin Polymers 0.000 description 2
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 238000007327 hydrogenolysis reaction Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 230000026045 iodination Effects 0.000 description 2
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 2
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- ZCSHNCUQKCANBX-UHFFFAOYSA-N lithium diisopropylamide Chemical compound [Li+].CC(C)[N-]C(C)C ZCSHNCUQKCANBX-UHFFFAOYSA-N 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000011976 maleic acid Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- JDSHMPZPIAZGSV-UHFFFAOYSA-N melamine powder Natural products NC1=NC(N)=NC(N)=N1 JDSHMPZPIAZGSV-UHFFFAOYSA-N 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 125000004365 octenyl group Chemical group C(=CCCCCCC)* 0.000 description 2
- 238000007410 oral glucose tolerance test Methods 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 2
- 229910052763 palladium Inorganic materials 0.000 description 2
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 2
- JYVLIDXNZAXMDK-UHFFFAOYSA-N pentan-2-ol Chemical compound CCCC(C)O JYVLIDXNZAXMDK-UHFFFAOYSA-N 0.000 description 2
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 230000000704 physical effect Effects 0.000 description 2
- 125000005936 piperidyl group Chemical group 0.000 description 2
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 235000019833 protease Nutrition 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 208000017520 skin disease Diseases 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000012312 sodium hydride Substances 0.000 description 2
- 229910000104 sodium hydride Inorganic materials 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- YBRBMKDOPFTVDT-UHFFFAOYSA-N tert-butylamine Chemical compound CC(C)(C)N YBRBMKDOPFTVDT-UHFFFAOYSA-N 0.000 description 2
- HJUGFYREWKUQJT-UHFFFAOYSA-N tetrabromomethane Chemical compound BrC(Br)(Br)Br HJUGFYREWKUQJT-UHFFFAOYSA-N 0.000 description 2
- FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- QAEDZJGFFMLHHQ-UHFFFAOYSA-N trifluoroacetic anhydride Chemical compound FC(F)(F)C(=O)OC(=O)C(F)(F)F QAEDZJGFFMLHHQ-UHFFFAOYSA-N 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- 239000008215 water for injection Substances 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- VIJSPAIQWVPKQZ-BLECARSGSA-N (2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-acetamido-5-(diaminomethylideneamino)pentanoyl]amino]-4-methylpentanoyl]amino]-4,4-dimethylpentanoyl]amino]-4-methylpentanoyl]amino]propanoyl]amino]-5-(diaminomethylideneamino)pentanoic acid Chemical compound NC(=N)NCCC[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(C)=O VIJSPAIQWVPKQZ-BLECARSGSA-N 0.000 description 1
- MDNLPMUOELGCNE-UHFFFAOYSA-N 1-(3-fluoropyrrolidin-1-yl)ethanone Chemical compound CC(=O)N1CCC(F)C1 MDNLPMUOELGCNE-UHFFFAOYSA-N 0.000 description 1
- PTSPKMINRZNMJA-UHFFFAOYSA-N 1-acetyl-4-fluoropyrrolidine-2-carbonitrile Chemical compound CC(=O)N1CC(F)CC1C#N PTSPKMINRZNMJA-UHFFFAOYSA-N 0.000 description 1
- PJUPKRYGDFTMTM-UHFFFAOYSA-N 1-hydroxybenzotriazole;hydrate Chemical compound O.C1=CC=C2N(O)N=NC2=C1 PJUPKRYGDFTMTM-UHFFFAOYSA-N 0.000 description 1
- DXUWLPMQHNMSOZ-UHFFFAOYSA-N 1-pyrrolidin-1-ylethanone;hydrochloride Chemical compound Cl.CC(=O)N1CCCC1 DXUWLPMQHNMSOZ-UHFFFAOYSA-N 0.000 description 1
- YQTCQNIPQMJNTI-UHFFFAOYSA-N 2,2-dimethylpropan-1-one Chemical group CC(C)(C)[C]=O YQTCQNIPQMJNTI-UHFFFAOYSA-N 0.000 description 1
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- 229940058020 2-amino-2-methyl-1-propanol Drugs 0.000 description 1
- LSTRKXWIZZZYAS-UHFFFAOYSA-N 2-bromoacetyl bromide Chemical compound BrCC(Br)=O LSTRKXWIZZZYAS-UHFFFAOYSA-N 0.000 description 1
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 1
- 125000001216 2-naphthoyl group Chemical group C1=C(C=CC2=CC=CC=C12)C(=O)* 0.000 description 1
- 125000003762 3,4-dimethoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C(OC([H])([H])[H])C([H])=C1* 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- HPBLSVCAHKLFDH-UHFFFAOYSA-N 3-fluoropyrrolidine-1-carbonitrile Chemical compound FC1CCN(C#N)C1 HPBLSVCAHKLFDH-UHFFFAOYSA-N 0.000 description 1
- KSPZEMCRWJMWJF-UHFFFAOYSA-N 3-fluoropyrrolidine-3-carbonitrile Chemical compound N#CC1(F)CCNC1 KSPZEMCRWJMWJF-UHFFFAOYSA-N 0.000 description 1
- LENYOXXELREKGZ-UHFFFAOYSA-N 3-fluoropyrrolidine;hydron;chloride Chemical compound Cl.FC1CCNC1 LENYOXXELREKGZ-UHFFFAOYSA-N 0.000 description 1
- QOXOZONBQWIKDA-UHFFFAOYSA-N 3-hydroxypropyl Chemical group [CH2]CCO QOXOZONBQWIKDA-UHFFFAOYSA-N 0.000 description 1
- HHFUFGKACHWIAV-UHFFFAOYSA-N 4-fluoropyrrolidine-2-carbonitrile Chemical compound FC1CNC(C#N)C1 HHFUFGKACHWIAV-UHFFFAOYSA-N 0.000 description 1
- SXIFAEWFOJETOA-UHFFFAOYSA-N 4-hydroxy-butyl Chemical group [CH2]CCCO SXIFAEWFOJETOA-UHFFFAOYSA-N 0.000 description 1
- 125000004203 4-hydroxyphenyl group Chemical group [H]OC1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- LQVMZVKOVPITOO-UHFFFAOYSA-N 9h-fluoren-1-ylmethyl carbonochloridate Chemical compound C1C2=CC=CC=C2C2=C1C(COC(=O)Cl)=CC=C2 LQVMZVKOVPITOO-UHFFFAOYSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- JDZTZMIBDZGRIZ-UHFFFAOYSA-N C[S](C)(F)(F)F Chemical compound C[S](C)(F)(F)F JDZTZMIBDZGRIZ-UHFFFAOYSA-N 0.000 description 1
- 101100459438 Caenorhabditis elegans nac-1 gene Proteins 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 1
- 229940124213 Dipeptidyl peptidase 4 (DPP IV) inhibitor Drugs 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 102000007446 Glucagon-Like Peptide-1 Receptor Human genes 0.000 description 1
- 108010086246 Glucagon-Like Peptide-1 Receptor Proteins 0.000 description 1
- 108010088406 Glucagon-Like Peptides Proteins 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- FRJIAZKQGSCKPQ-FSPLSTOPSA-N His-Ala Chemical group OC(=O)[C@H](C)NC(=O)[C@@H](N)CC1=CN=CN1 FRJIAZKQGSCKPQ-FSPLSTOPSA-N 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical group CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- LEVWYRKDKASIDU-IMJSIDKUSA-N L-cystine Chemical compound [O-]C(=O)[C@@H]([NH3+])CSSC[C@H]([NH3+])C([O-])=O LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 101710151321 Melanostatin Proteins 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 1
- NDTPKYSIFCRAGZ-UHFFFAOYSA-N N-(trifluoro-lambda4-sulfanyl)methanamine Chemical compound CNS(F)(F)F NDTPKYSIFCRAGZ-UHFFFAOYSA-N 0.000 description 1
- NRTJUQBZRAZJQB-UHFFFAOYSA-N NCCNC1N(C=CC=C1)[N+](=O)[O-] Chemical compound NCCNC1N(C=CC=C1)[N+](=O)[O-] NRTJUQBZRAZJQB-UHFFFAOYSA-N 0.000 description 1
- 102400000064 Neuropeptide Y Human genes 0.000 description 1
- 108090000189 Neuropeptides Proteins 0.000 description 1
- 102000003797 Neuropeptides Human genes 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 102000012479 Serine Proteases Human genes 0.000 description 1
- 108010022999 Serine Proteases Proteins 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 244000299461 Theobroma cacao Species 0.000 description 1
- 235000009470 Theobroma cacao Nutrition 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 239000006096 absorbing agent Substances 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 150000001266 acyl halides Chemical class 0.000 description 1
- 125000004423 acyloxy group Chemical group 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- CBTVGIZVANVGBH-UHFFFAOYSA-N aminomethyl propanol Chemical compound CC(C)(N)CO CBTVGIZVANVGBH-UHFFFAOYSA-N 0.000 description 1
- VZTDIZULWFCMLS-UHFFFAOYSA-N ammonium formate Chemical compound [NH4+].[O-]C=O VZTDIZULWFCMLS-UHFFFAOYSA-N 0.000 description 1
- 239000012491 analyte Substances 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- IGIDLTISMCAULB-UHFFFAOYSA-N anteisohexanoic acid Natural products CCC(C)CC(O)=O IGIDLTISMCAULB-UHFFFAOYSA-N 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 235000009697 arginine Nutrition 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 125000004104 aryloxy group Chemical group 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 150000003939 benzylamines Chemical class 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 125000002619 bicyclic group Chemical group 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 239000004305 biphenyl Substances 0.000 description 1
- 235000010290 biphenyl Nutrition 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 239000004067 bulking agent Substances 0.000 description 1
- 239000001273 butane Substances 0.000 description 1
- 125000004369 butenyl group Chemical group C(=CCC)* 0.000 description 1
- 125000004063 butyryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- RBHJBMIOOPYDBQ-UHFFFAOYSA-N carbon dioxide;propan-2-one Chemical compound O=C=O.CC(C)=O RBHJBMIOOPYDBQ-UHFFFAOYSA-N 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 230000020411 cell activation Effects 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- QOPVNWQGBQYBBP-UHFFFAOYSA-N chloroethyl chloroformate Chemical compound CC(Cl)OC(Cl)=O QOPVNWQGBQYBBP-UHFFFAOYSA-N 0.000 description 1
- WORJEOGGNQDSOE-UHFFFAOYSA-N chloroform;methanol Chemical compound OC.ClC(Cl)Cl WORJEOGGNQDSOE-UHFFFAOYSA-N 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 238000006482 condensation reaction Methods 0.000 description 1
- GLNDAGDHSLMOKX-UHFFFAOYSA-N coumarin 120 Chemical compound C1=C(N)C=CC2=C1OC(=O)C=C2C GLNDAGDHSLMOKX-UHFFFAOYSA-N 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- MGNCLNQXLYJVJD-UHFFFAOYSA-N cyanuric chloride Chemical compound ClC1=NC(Cl)=NC(Cl)=N1 MGNCLNQXLYJVJD-UHFFFAOYSA-N 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- ARUKYTASOALXFG-UHFFFAOYSA-N cycloheptylcycloheptane Chemical group C1CCCCCC1C1CCCCCC1 ARUKYTASOALXFG-UHFFFAOYSA-N 0.000 description 1
- NLUNLVTVUDIHFE-UHFFFAOYSA-N cyclooctylcyclooctane Chemical group C1CCCCCCC1C1CCCCCCC1 NLUNLVTVUDIHFE-UHFFFAOYSA-N 0.000 description 1
- MAWOHFOSAIXURX-UHFFFAOYSA-N cyclopentylcyclopentane Chemical group C1CCCC1C1CCCC1 MAWOHFOSAIXURX-UHFFFAOYSA-N 0.000 description 1
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 description 1
- 229960003067 cystine Drugs 0.000 description 1
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 239000003603 dipeptidyl peptidase IV inhibitor Substances 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
- 125000004705 ethylthio group Chemical group C(C)S* 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
- 239000012520 frozen sample Substances 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 230000030136 gastric emptying Effects 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- VKYKSIONXSXAKP-UHFFFAOYSA-N hexamethylenetetramine Chemical compound C1N(C2)CN3CN1CN2C3 VKYKSIONXSXAKP-UHFFFAOYSA-N 0.000 description 1
- 125000006038 hexenyl group Chemical group 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 108010040030 histidinoalanine Proteins 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 1
- 229940125721 immunosuppressive agent Drugs 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 239000002198 insoluble material Substances 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- 125000000555 isopropenyl group Chemical group [H]\C([H])=C(\*)C([H])([H])[H] 0.000 description 1
- 125000003253 isopropoxy group Chemical group [H]C([H])([H])C([H])(O*)C([H])([H])[H] 0.000 description 1
- JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- XGZVUEUWXADBQD-UHFFFAOYSA-L lithium carbonate Chemical compound [Li+].[Li+].[O-]C([O-])=O XGZVUEUWXADBQD-UHFFFAOYSA-L 0.000 description 1
- 229910052808 lithium carbonate Inorganic materials 0.000 description 1
- 229910003002 lithium salt Inorganic materials 0.000 description 1
- 159000000002 lithium salts Chemical class 0.000 description 1
- MAZKNBXUMANNDL-UHFFFAOYSA-M lithium;2-ethylhexanoate Chemical compound [Li+].CCCCC(CC)C([O-])=O MAZKNBXUMANNDL-UHFFFAOYSA-M 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 150000002668 lysine derivatives Chemical class 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 125000002816 methylsulfanyl group Chemical group [H]C([H])([H])S[*] 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- IJDNQMDRQITEOD-UHFFFAOYSA-N n-butane Chemical compound CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 description 1
- OFBQJSOFQDEBGM-UHFFFAOYSA-N n-pentane Natural products CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- URPYMXQQVHTUDU-OFGSCBOVSA-N nucleopeptide y Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=C(O)C=C1 URPYMXQQVHTUDU-OFGSCBOVSA-N 0.000 description 1
- 125000005441 o-toluyl group Chemical group [H]C1=C([H])C(C(*)=O)=C(C([H])=C1[H])C([H])([H])[H] 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 125000005740 oxycarbonyl group Chemical group [*:1]OC([*:2])=O 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 125000003538 pentan-3-yl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000002255 pentenyl group Chemical group C(=CCCC)* 0.000 description 1
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N phenylbenzene Natural products C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 1
- 235000011007 phosphoric acid Nutrition 0.000 description 1
- 150000003018 phosphorus compounds Chemical group 0.000 description 1
- FAIAAWCVCHQXDN-UHFFFAOYSA-N phosphorus trichloride Chemical compound ClP(Cl)Cl FAIAAWCVCHQXDN-UHFFFAOYSA-N 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000002572 propoxy group Chemical group [*]OC([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
- 208000023958 prostate neoplasm Diseases 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- ALSCEGDXFJIYES-UHFFFAOYSA-N pyrrolidine-2-carbonitrile Chemical class N#CC1CCCN1 ALSCEGDXFJIYES-UHFFFAOYSA-N 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 229910052702 rhenium Inorganic materials 0.000 description 1
- 229910052701 rubidium Inorganic materials 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical class O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 1
- 229940079827 sodium hydrogen sulfite Drugs 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- RLNKVYQAJLLYGU-UHFFFAOYSA-M sodium;2-butyloctanoate Chemical compound [Na+].CCCCCCC(C([O-])=O)CCCC RLNKVYQAJLLYGU-UHFFFAOYSA-M 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 125000005017 substituted alkenyl group Chemical group 0.000 description 1
- 125000005346 substituted cycloalkyl group Chemical group 0.000 description 1
- 238000009495 sugar coating Methods 0.000 description 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 125000006633 tert-butoxycarbonylamino group Chemical group 0.000 description 1
- 125000006318 tert-butyl amino group Chemical group [H]N(*)C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 125000003774 valeryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 125000002114 valyl group Chemical group 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Definitions
- the present invention relates to a novel Mi derivative (Background Art
- DPP IV Dipidyl peptidase IV
- DPP IV is a type of serine protease that hydrolyzes dipeptides from peptide chains having proline or alanine at the second position from the N-terminus.
- DPP IV is widely distributed in tissues such as kidney and liver and plasma, and is involved in the metabolism of various bioactive peptides.
- DPP IV is involved in the metabolism of glucagon-like peptide 11 (GLP-1).
- DPPIV inactivates GLP-1 by hydrolyzing the dipeptide at the N-terminal His-Ala of GLP-1, and the inactivated form acts as an antagonist of the GLP-1 receptor. I have.
- GLP-1 has physiological actions of promoting secretion of insulin from the kidney, prolonging the gastric emptying time, and suppressing feeding. Therefore, inhibition of DPPIV can enhance the action of GLP-1, enhance insulin action and improve glucose metabolism, and is expected to be useful for the treatment of type 2 diabetes.
- DPP IV is involved in the metabolism of neuropeptide Y, a neuropeptide, activation of T cells, which are immunocompetent cells, adhesion of cancer cells to endothelium, and entry of HIV virus into lymphocytes.
- T cells which are immunocompetent cells
- adhesion of cancer cells to endothelium and entry of HIV virus into lymphocytes.
- An object of the present invention is to provide a novel cyanopia lysine derivative exhibiting excellent DPPIV inhibitory activity in a living body and having physical properties required for a drug such as stability.
- the present invention provides a compound of formula (1)
- W is an acyl group derived from a natural amino acid
- W 1 represents an alkanoyl group having 1 to 5 carbon atoms, an arylcarbonyl group which may be substituted or an alkyl group having 1 to 5 carbon atoms
- W 2 represents a hydrogen atom or an alkyl group having 1 to 5 carbon atoms.
- W 3 and W 4 are the same or different and each represent a hydrogen atom or an alkyl group having 1 to 5 carbon atoms.
- X represents an oxygen atom or a sulfur atom
- Y is the formula — CR 5 R 6 — [wherein R 5 and R 6 are the same or different and are a hydrogen atom; a halogen atom; a halogen atom, a zK acid group, a hydroxyalkyl group having 1 to 5 carbon atoms, a carboxyl group.
- R 14 represents a linear alkyl group or a benzyl group having 1 to 5 carbon atoms.
- the carbon number 1 which may be substituted with one or more groups selected from the group consisting of To 10 alkyl groups; or may be substituted with one or more groups selected from the group consisting of a halogen atom, a hydroxyl group, a propyloxyl group, an amino group, an aminocarbonyl group and a linear alkoxy group having 1 to 5 carbon atoms. It represents an alkenyl group having 2 to 10 carbon atoms.
- R 7 , R 8 , R 9 and R 1 ° are the same or different and are a hydrogen atom; a halogen atom; a halogen atom, a hydroxyl group, C1-C5 hydroxyalkyl group, carboxyl group, mercapto group, C1-C5 alkylthio group , Guanidyl group, phenyl group which may be substituted, imidazolyl group, indolyl group
- R 11 represents a hydrogen atom, a phenyl group which may be substituted, a pyridyl group which may be substituted, a tert-butoxycarpenyl group or a benzyloxycarponyl group
- R 12 represents a hydrogen atom or — (CH 2 ) m -R 13 (where m represents an integer of 1 to 5, R 13 represents a hydrogen atom, a methoxycarbonyl group, an ethoxycarbonyl group or a benzyloxy And a carboxyl group.
- R 14 represents a linear alkyl group or a benzyl group having 1 to 5 carbon atoms
- R 14 represents a linear alkyl group or a benzyl group having 1 to 5 carbon atoms
- a cycloalkyl group having 3 to 8 carbon atoms which may be substituted with one or more groups selected from the group consisting of an alkyl group and a linear alkoxy group having 1 to 5 carbon atoms
- Z is a hydrogen atom; or a halogen atom, a hydroxyl group, a hydroxyalkyl group having 1 to 5 carbon atoms, a carboxyl group, a mercapto group, an alkylthio group having 1 to 5 carbon atoms, a guanidyl group, a phenyl group which may be substituted, and imidazolyl.
- R 12 is a hydrogen atom or one (CH 2 ) -R 13 (formula In the formula, m represents an integer of 1 to 5, and R 13 represents a hydrogen atom, a methoxycarbonyl group, an ethoxycarbonyl group, or a benzyloxycarbonyl group. .).
- R 14 represents a linear alkyl group or a benzyl group having 1 to 5 carbon atoms. Represents an alkyl group of 1 to 10 or
- Y and Z are joined together with an adjacent nitrogen atom to form a halogen atom, a hydroxyl group, an amino group, a chain alkyl group having 1 to 5 carbon atoms and one OR 15 (wherein, R 15 is a group having 1 to 5 carbon atoms) And 5 represents a chain alkyl group, an aminocarbonylmethyl group or a benzyl group.5) which forms a cyclic amino group having 2 to 10 carbon atoms which may be substituted with one or more groups selected from the group consisting of: ]
- the compound which is a cyanopyrrolidine derivative represented by these, or its pharmacologically acceptable salt is provided.
- a compound according to the present invention wherein in formula (1), Y is —CH 2 —, and Z is selected from the group consisting of a hydroxyl group and a hydroxyalkyl group having 1 to 5 carbon atoms.
- a cyanopyrrolidine derivative which is a branched or cyclic alkyl group having 4 to 10 carbon atoms, or a pharmaceutically acceptable salt thereof, which may be substituted.
- the present invention provides a compound of the formula (1) wherein Y is —CH 2 — and Z is a tert-butyl group, a (1-hydroxymethyl) cyclopentyl group or a (2-hydroxy_1
- a cyanopyrrolidine derivative represented by the formula (1), wherein Y is -CR 5 R 6 — wherein R 5 is hydrogen and Z is a hydrogen atom. Or a pharmaceutically acceptable salt thereof.
- the present invention provides a compound of the formula (1), wherein Y is one CR 5 R 6 — (wherein R 5 is hydrogen and R 6 is a branched or branched C 3-6 carbon atom. A cyclic alkyl group), wherein Z is a hydrogen atom, or a pharmaceutically acceptable salt thereof.
- the present invention provides a compound of the formula (1) wherein Y is —CH [CH (CH 3 ) 2 ] —, CH (C (CH 3 ) 3 ] — or —CH [GH (CH 3 ) A compound which is CH 2 CH 3 ] — and is a cyanopyrrolidine derivative or a pharmaceutically acceptable salt thereof, wherein Z is a hydrogen atom.
- a medicament comprising the compound of the present invention or a pharmaceutically acceptable salt thereof as an active ingredient.
- the aforementioned medicament for preventing or treating a disease or condition that can be ameliorated by inhibiting dipeptidyl peptidase IV.
- the medicament wherein the disease or condition that can be ameliorated by inhibiting the dipeptidyl peptidase IV is diabetes.
- the medicament wherein the disease or condition ameliorated by inhibiting the dipeptidyl peptidase IV is an immune disease.
- chain means a linear or branched chain.
- Asyl groups derived from natural amino acids include, for example, alanine, arginine, asparagine, aspartic acid, cystine, glutamine, glutamic acid, glycine (i.e., aminoacetyl group), histidine, isoleucine, leucine, lysine, methionine, fenylalanine, Examples include acyl groups derived from proline, serine, threonine, tyrosine, valine and the like.
- the halogen atom means a fluorine atom, a chlorine atom, a bromine atom or an iodine atom.
- the alkoxy group having 1 to 5 carbon atoms means a linear, branched or cyclic alkoxy group, for example, methoxy group, ethoxy group, propoxy group, isopropoxy group, Butoxy, isobutoxy, tert-butoxy, cyclopropylmethoxy, pentyloxy, isopentyloxy and the like.
- the alkanoyl group having 1 to 5 carbon atoms means a linear or branched alkanoyl group, such as formyl group, acetyl group, propionyl group, butyryl group, isobutyryl group, valeryl group, isovaleryl group, pivaloyl group. And so on.
- the arylcarbonyl group which may be substituted means a substituted or unsubstituted arylcarbonyl group, for example, a benzyl group, an 11-naphthoyl group, a 2-naphthoyl group and the like.
- an o-toluyl group can be mentioned.
- the alkyl group having 1 to 5 carbon atoms means a linear, branched or cyclic alkyl group, for example, a methyl group, an ethyl group, a propyl group, an isopropyl group, a cyclopropyl group, a butyl group, an isobutyl group.
- the alkyl group having 1 to 10 carbon atoms which may be substituted means a substituted or unsubstituted linear, branched or cyclic alkyl group having 1 to 10 carbon atoms, for example, a methyl group, Ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, isopentyl, hexyl, heptyl, octyl, noel, decyl, carbon number 3-10 cycloalkyl groups (for example, cyclopropyl group, cyclobutyl group, cyclopentyl group, cyclobutylmethyl group, cyclohexyl group, cycloheptyl group, cyclooctyl group, etc.), cycloalkenyl group having 4-8 carbon atoms (For example, cyclobutenyl group, cyclopentenyl group,
- the substituted phenyl group of the phenyl group which may be substituted is, for example, substituted with one or more groups selected from the group consisting of a hydroxyl group and a linear or branched alkoxy group having 1 to 5 carbon atoms. Phenyl groups (eg, 4-hydroxyphenyl group, 3,4-dimethoxyphenyl group, etc.).
- the substituted pyridyl group of a pyridyl group which may be substituted is, for example, selected from the group consisting of a cyano group, a nitro group, a halogen atom, and an aminocaprol group.
- Pyridyl groups substituted with one or more of the following groups for example, 5-cyanopyridine-12-yl group, 5-ditropyridine-12-yl group, 5-cyclopentylpyridine-2-yl group, Minocarbonylpyridine-2-yl group).
- Hydroxyalkyl groups having 1 to 5 carbon atoms include hydroxymethyl group, 1-hydroxyl group, 2-hydroxyethyl group, 1-hydroxypropyl group and 2-hydrido Roxypropyl, 3-hydroxypropyl, 1- (hydroxymethyl) ethyl, 1-hydroxy-1-methylethyl, 4-hydroxybutyl, 5-hydroxypentyl and the like.
- alkylthio group having 1 to 5 carbon atoms examples include a methylthio group, an ethylthio group, a propylthio group, an isopropylthio group, a butylthio group, a tert-butylthio group, and a pentylthio group.
- the optionally substituted alkenyl group having 2 to 10 carbon atoms means a substituted or unsubstituted linear, branched or cyclic alkenyl group having 2 to 10 carbon atoms, for example, a vinyl group or an aryl group.
- Alkenyl groups such as a benzyl group, a propenyl group, an isopropenyl group, a butenyl group, an isobutenyl group, a pentenyl group, a hexenyl group, a heptenyl group, an octenyl group, a cyclopentenyl group, and a cyclohexenyl group.
- Alkenyl groups can be mentioned.
- the optionally substituted cycloalkyl group having 3 to 8 carbon atoms means a substituted or unsubstituted cycloalkyl group, for example, a cyclopropyl group, a cyclobutyl group, a cyclopentyl group, a cyclohexyl group, a cyclohexyl group.
- cycloalkyl groups such as butyl group and cyclooctyl group
- hydrogen atoms of these cycloalkyl groups can be replaced with halogen atoms, hydroxyl groups, hydroxyl groups, amino groups, aminocarbonyl groups, linear or branched carbon atoms. Examples thereof include a cycloalkyl group substituted with one or more groups selected from the group consisting of an alkyl group having 1 to 5 prime numbers and a linear or branched alkoxy group having 1 to 5 carbon atoms.
- a cycloalkenyl group having up to 8 means a substituted or unsubstituted cycloalkenyl group, for example, cyclobutenyl group, cyclopentenyl group, cyclohexenyl group, cycloheptenyl group, cyclooctenyl group, etc.
- cycloalkenyl groups are replaced by halogen atoms, hydroxyl groups, propyloxyl groups, amino groups, aminocarbonyl groups, linear or branched alkyl groups having 1 to 5 carbon atoms and Linear or branched C1-C5 alkoxy group
- the optionally substituted bicycloalkyl group having 5 to 10 carbon atoms means a substituted or unsubstituted bicycloalkyl group, for example, a bicyclopentyl group, a bicyclohexyl group, a bicycloheptyl group, a bicyclooctyl group,
- bicycloalkyl groups such as a bicyclononyl group and a bicyclodecyl group
- hydrogen atoms of these bicycloalkyl groups are replaced with halogen atoms, hydroxyl groups, carbonyl groups, amino groups, aminoamino groups, linear or branched carbon atoms of 1 to 1.
- Examples thereof include a bicycloalkyl group substituted with one or more groups selected from the group consisting of an alkyl group of 5 and a linear or branched alkoxy group having 1 to 5 carbon atoms.
- the optionally substituted bicycloalkenyl group having 5 to 10 carbon atoms means a substituted or unsubstituted bicycloalkenyl group, for example, a bicyclopentenyl group, a bicyclohexenyl group, a bicycloheptenyl group, a bicyclo
- bicycloalkenyl groups such as octenyl group, bicyclononel group and bicyclodecel group
- hydrogen atoms of these bicycloalkenyl groups are replaced with halogen atoms, hydroxyl groups, carbonyl groups, amino groups, aminoamino groups, linear or branched chains.
- the optionally substituted cyclic amino group having 2 to 10 carbon atoms refers to a substituted or unsubstituted amino group having one or more nitrogen atoms in the ring and optionally having one or more oxygen atoms and sulfur atoms.
- a hydrogen atom of a cyclic amino group in which a benzene ring or a pyridine ring is condensed to these cyclic amino groups or a hydrogen atom of a cyclic amino group (including a benzene ring or a pyridine ring condensed with a cyclic amino group) is a halogen atom, a hydroxyl group, an amino group, or the like.
- salts include, for example, salts with mineral acids such as sulfuric acid, hydrochloric acid, hydrobromic acid, and phosphoric acid, acetic acid, oxalic acid, lactic acid, tartaric acid, fumaric acid, maleic acid, and trifluoroacetic acid. And salts with organic acids such as methanesulfonic acid. The preferred embodiment of the compound of the present invention is shown.
- Z represents a hydroxyl group, an alkoxyl group having 1 to 5 carbon atoms, a hydroxyalkyl group having 1 to 5 carbon atoms, a phenyl group which may be substituted and NH R 1 1 may be substituted with (wherein R 1 1 is a pyridyl group which may be substituted) of the group consisting of one or more, preferably an alkyl group having a carbon number of 1 to 1 0.
- Z is preferably substituted with one or more of a group consisting of a hydroxyl group, a hydroxyalkyl group having 1 to 5 carbon atoms and an alkoxyl group having 1 to 5 carbon atoms.
- a branched or cyclic alkyl group more preferably a substituted or unsubstituted alkyl group having 4 to 10 carbon atoms, which may be substituted with at least one of a group consisting of a hydroxyl group and a hydroxyalkyl group having 1 to 5 carbon atoms.
- Y is a group represented by the formula —CR 5 R 6 — (wherein R 5 is hydrogen and R 6 may be substituted with an alkyl group having 1 to 10 carbon atoms or a group represented by the formula CR 7 R s _ CR 9 R 1 ° — (where R 8 and R 1 Q are hydrogen, and R 7 and R 9 are taken together with adjacent carbon atoms to form a cycloalkyl group having 3 to 8 carbon atoms)
- Z is preferably H or CH 3 .
- Y is a group represented by the formula _CR 5 R 6 — ⁇ wherein R 5 is hydrogen, R 6 is a hydroxyl group and one OR 14 (where R "is a linear group having 1 to 5 carbon atoms) Or a branched or branched alkyl group or a benzyl group), which is a branched or cyclic alkyl group having 3 to 6 carbon atoms which may be substituted with one or more selected from the group consisting of Z is a hydrogen atom, more preferably Y is CR 5 R 6 — wherein R 5 is hydrogen , R 6 is a branched or cyclic alkyl group having 3 to 6 carbon atoms), Z is a hydrogen atom, and still more preferably, Y is one CH [CH (CH 3 ) 2 ] _, When it is one CH [C (CH 3 ) 3] — or one CH [CH (CH 3 ) CH 2 CH 3 ] —, Z is a hydrogen atom
- Y and Z together with an adjacent nitrogen atom form a cyclic amino group having 2 to 10 carbon atoms which may be substituted include a pyrrolidyl group and a piperidyl group A group or a cyclic amino group in which a benzene ring is condensed to these groups, and preferred substituents include a hydroxyl group and one OR 15 (wherein R 15 is as defined above).
- the basicity of the nitrogen atom is attenuated by the presence of W, and the instability of the compound derived from the basicity of the nitrogen atom is improved.
- W greatly reduces the dipeptidyl peptidase IV inhibitory activity of the compound of the present invention
- the W portion is eliminated by an enzyme or the like in vivo, and the dipeptidyl peptidase IV activity is reduced. Strongly inhibits. That is, using a general expression, the compound of the present invention belongs to the category of a prodrug.
- the introduction of W has effects such as improvement of oral absorbability and continuation of drug activity, and enables reduction of the dose and the number of times of administration.
- the compound of the present invention can suppress dipeptidyl peptidase IV in a living body, thereby enhancing insulin action and improving glucose metabolism. It can contribute to suppressing cell activation, suppressing adhesion of cancer cells to endothelium, and preventing HIV virus from entering lymphocytes.
- the present invention relates to a disease or condition that can be improved by inhibiting dipeptidyl peptidase IV, for example, diabetes (particularly type 2), immune disease, arthritis, obesity, osteoporosis, glucose tolerance damage.
- diabetes particularly type 2
- immune disease arthritis
- obesity obesity
- osteoporosis glucose tolerance damage.
- the present invention provides the above-mentioned medicament for preventing or treating conditions, benign prostatic hypertrophy, skin diseases and the like.
- Immunosuppressive agents in tissue transplantation; for example, cytokine inhibitory inhibitors in various autoimmune diseases such as inflammatory bowel disease, multiple sclerosis, and rheumatoid arthritis (RA); Drugs useful in the prevention and treatment of AIDS by preventing HIV from entering cells, preventing metastasis, especially preventing breast and prostate tumors from metastasizing to the lungs Drugs and the like.
- the medicament of the present invention can be administered systemically or locally orally or rectally, subcutaneously, intramuscularly, intravenously, transdermally, or the like.
- the compound of the present invention in any form of a solid composition, a liquid composition, and other compositions, and an optimum one is selected as necessary.
- the medicament of the present invention can be produced by compounding a pharmaceutically acceptable carrier with the compound of the present invention. Specifically, conventional excipients, extenders, binders, disintegrants, coating agents, sugar coatings, pH adjusters, solubilizers, or aqueous or non-aqueous solvents, etc. are added, and by conventional formulation techniques, They can be prepared into tablets, pills, capsules, granules, powders, powders, solutions, emulsions, suspensions, injections, and the like.
- Excipients and bulking agents include, for example, lactose, magnesium stearate, starch, talc, gelatin, agar, pectin, acacia, olive oil, sesame oil, cocoa batata, ethylene glycol, and others. You can give something.
- the compound of the present invention can be formulated by forming an inclusion compound with j3, arcyclodextrin, methylated cyclodextrin and the like.
- the dose of the compound of the present invention varies depending on the disease, symptom, body weight, age, sex, administration route and the like, but is preferably about 1 to about 100 mg / person / day for oral administration to an adult. More preferably, the dose is about 10 to about 200 mg / day, which can be administered once or several times a day.
- the compound of the formula (1) can be produced by the following general production method.
- A represents a leaving group such as a halogen atom.
- This method is a method of introducing an oxypropyl group into an amino group, and further converting A, which is a leaving group, to W 1 .
- an oxycarbonyl group can be introduced using 1-chloroalkyl formate in the presence of a suitable base.
- a suitable base include amines such as triethylamine and disopropylethylamine, and inorganic bases such as carbonated lime.
- the reaction solvent include dichloromethane, chloroform, 1,2-dichloromethane, N, N-dimethylformamide, tetrahydrofuran, dioxane, toluene, ethyl acetate and the like. The reaction can be performed at -50 to 50 ° C.
- An example of converting A, which is a leaving group, to W 1 is a method of introducing an acyloxy group using a carboxylic acid sodium salt when A is a chlorine atom.
- sodium iodide, potassium iodide, or the like that promotes the reaction can be used.
- the reaction solvent include dichloromethane, chloroform, 1,2-dichloroethane, N, N-dimethylformamide, tetrahydrofuran, dioxane, toluene, and ethyl acetate.
- the reaction can be performed at -50 to 50 ° C. Anti
- This method is to introduce an oxypropyl group into an amino group.
- a 1-acyloxyalkoxycarbonyl group can be introduced.
- an appropriate base can be used.
- the base include amines such as triethylamine and diisopropylethylamine, and inorganic bases such as potassium carbonate.
- the reaction solvent include dichloromethane, chloroform, 1,2-dichloroethane, ⁇ , ⁇ -dimethylformamide, tetrahydrofuran, dioxane, ruene, and ethyl acetate. The reaction can be carried out at a temperature of 50-50 ° C. Reaction formula 3
- W 5 represents an acyl group derived from a natural amino acid and having an amino group protected, and W 5 represents an acyl group derived from a natural amino acid. Represents a group.
- an acyl group derived from a natural amino acid and having an amino group protected is introduced and further deprotected.
- the amidation reaction can be carried out using an acyl halide such as acyl chloride or bromide in a solvent that does not participate in the reaction, such as dichloromethane, chloroform, 1,2-dichloroethane, tetrahydrofuran, dioxane, toluene, and ethyl acetate.
- the reaction can be performed using a base.
- Examples of the base include amines such as triethylamine and diisopropylethylamine, sodium 2-ethylhexanoate, and lithium 2-ethylhexanoate.
- Inorganic bases such as organic acid salts and potassium carbonate; These reactions can be performed at 150-100 ° C.
- the reaction can be carried out using an active ester such as 1-benzotriazolyl ester / succinimidyl ester.
- active ester such as 1-benzotriazolyl ester / succinimidyl ester.
- the reaction solvent include dichloromethane, chloroform, 1,2-dichloroethane, N, N-dimethylformamide, tetrahydrofuran, dioxane, toluene, and ethyl acetate.
- the reaction can be performed at -50 to 50 ° C.
- amidation can be performed using a carboxylic acid and a dehydrating condensing agent.
- the dehydration condensing agent include 1-ethyl-3- (3-dimethylaminopropyl) carbodiimide hydrochloride, dicyclohexyl carbodiimide, diphenylphosphoryl azide, and phenyldiimidazole.
- Activators such as 1-hydroxybenzotriazole and hydroxysuccinimide can be used accordingly.
- reaction solvent examples include dichloromethane, chloroform, 1,2-dichloroethane, N, N-dimethylformamide, tetrahydrofuran, dioxane, toluene, and ethyl acetate.
- the reaction can be carried out using a base.
- the base include amines such as triethylamine and diisopropylethylamine, and inorganic bases such as potassium carbonate.
- the reaction can be carried out at a temperature of 150 to 50 ° C. Further, for example, amidation can be carried out using a mixed acid anhydride obtained from carboxylic acid and chlorocarbonate.
- the solvent for these reactions is examples of solvents that do not participate in the reaction include furan, dioxane, dichloromethane, chloroform, N, N-dimethylformamide, toluene, and ethyl acetate.
- the reaction can be carried out using a base.
- the base include amines such as triethylamine and diisopropylethylamine, and inorganic bases such as carbon dioxide lime.
- the organic solvent examples include ethanol, methanol, tetrahydrofuran, N, N-dimethylformamide, dichloromethane, chloroform, 1,2-dichloromethane, and the like.
- the protecting group is benzyloxy
- a hydrogenolysis reaction such as a carbonyl group
- a metal catalyst such as palladium.
- a solvent that does not participate in the reaction such as ethanol, methanol, tetrahydrofuran, and ethyl acetate can be used.
- the reaction can be performed at O-100 ° C.
- hydrogen gas can be used for this reaction, or the reaction can be performed using a combination of reagents such as ammonium formate and formate.
- a base such as getylamine, piperidine, ammonia, sodium hydroxide, potassium carbonate or the like is used. Can be deprotected. These bases can be used alone or diluted, dissolved or suspended in a solvent. At this time, water, ethanol, methanol, tetrahydrofuran, N, N —Dimethylformamide, dichloromethane, chloroform, 1,2-dichloroethane and the like can be used. The reaction can be performed at O-100 ° C.
- a compound in which the protecting group is a group that can be deprotected by a metal catalyst such as an aryloxy group
- a metal catalyst such as an aryloxy group
- tetrakis (triphenylphosphine) palladium as a catalyst or a reagent.
- the reaction can be carried out in a solvent that does not participate in the reaction, such as dichloromethane, chloroform, tetrahydrofuran, and the like.
- the reaction can be performed at 0-1 oo ° c.
- W 3 —C ⁇ —CH2C (W 4 ) — (where W 3 and W 4 are each a hydrogen atom or an alkyl group having 1 to 5 carbon atoms) is introduced into an amino group.
- it can be synthesized by a dehydration-condensation reaction of a / 3-diketone such as acetylacetone with an amine compound.
- the reaction can be performed using a base or an acid.
- the base include amines such as triethylamine and diisopropylethylamine, and inorganic bases such as potassium carbonate.
- Examples of the acid include hydrochloric acid, acetic acid, sulfuric acid, trifluoroacetic acid, p-toluenesulfonic acid, methanesulfonic acid and the like.
- Solvents for these reactions include solvents that do not participate in the reaction, such as tetrahydrofuran, dioxane, dichloromethane, chloroform, N, N-dimethylformamide, toluene, and ethyl acetate. These reactions can be performed at 0 to 50 ° C. Reaction formula 5
- Ra represents a cyano group, an aminocarboyl group or an alkoxyl group
- Rb represents a protecting group for an amino group
- R 1 represents a fluorine atom or a hydroxyl group.
- Rc represents a leaving group such as a halogen atom or a sulfonyloxy group, or a group that can be converted to a leaving group.
- Rc is a leaving group such as a chlorine atom, a bromine atom, an iodine atom, a methanesulfonyloxy group, a p-toluenesulfonyloxy group, are ethylamine, isopropylamine, tert-butylamine, benzylamine, substituted benzylamine,
- the substitution reaction can be performed using primary amines (Z-NH 2 ) such as phenethylamine, substituted phenethylamine, and 2- (substituted pyridylamino) ethylamine.
- these amines may be used in excess or a base may be separately added.
- the base to be added include amines such as triethylamine and diisopropylethylamine, and inorganic bases such as potassium carbonate. Also, in some cases, Sodium iodide or the like can be added to proceed.
- the reaction solvent such as triethylamine and diisopropylethylamine, and inorganic bases such as potassium carbonate.
- Sodium iodide or the like can be added to proceed.
- reaction can be performed at 0-100 ° C.
- Examples of a group that can convert R c to a leaving group include a hydroxyl group.
- a group that can convert R c to a leaving group include a hydroxyl group.
- the chlorination reaction include a method using carbon tetrachloride and triphenylphosphine, a method using phosphorous chloride, or a method using tosyl chloride or the like as a leaving group, followed by replacement with lithium salt or the like. can give.
- a solvent that does not participate in the reaction such as tetrahydrofuran, dioxane, dichloromethane, chloroform, N, N-dimethylformamide, or the like can be used.
- These reactions can be performed at —50-100 ° C.
- An example of the bromination reaction is a method using carbon tetrabromide and triphenylphosphine. This reaction can be carried out at 150 to 50 ° C. using a solvent which does not participate in the reaction, such as tetrahydrofuran, dioxane, dichloromethane, chloroform, N, N-dimethylformamide and the like.
- Examples of iodination reactions include methods using iodine, triphenylphosphine and imidazole. This reaction can use a solvent that does not participate in the reaction, such as tetrahydrofuran, dioxane, dichloromethane, chloroform, N, N-dimethylformamide, and the like. These reactions can be performed at —50 to 100 ° C. Methanesulfonylation and p-toluenesulfonylation can be carried out using methanesulfonyl chloride, p-toluenesulfonyl chloride and the like, respectively. At this time, a suitable base may be added.
- Examples of the base to be added include amines such as triethylamine and diisopropylethylamine and inorganic bases such as carbonated lime.
- Examples of the reaction solvent include solvents that do not participate in the reaction, such as N, N-dimethylformamide, tetrahydrofuran, dioxane, dichloromethane, chloroform, 1,2-dichloroethane, and the like. Can be done in C. Reaction formula 7
- R c is a chlorine atom, a bromine atom, an iodine atom, a methanesulfonyloxy group
- R c is a chlorine atom, a bromine atom, an iodine atom, a methanesulfonyloxy group
- p The compound which is a leaving group such as —toluenesulfonyloxy group is subjected to a substitution reaction using a compound represented by Z—NH—R b (wherein Z and R b are the same as described above).
- Z—NH—R b wherein Z and R b are the same as described above.
- sodium hydride, potassium tert-butoxide, n-butyllithium, lithium diisopro R pyramide and the like can be used as the base.
- N N-dimethylformamide, tetrahydrofuran, dioxane and the like can be used.
- the reaction can be performed at -50
- Examples of a group that can convert R c to a leaving group include a hydroxyl group.
- Rd represents a leaving group such as a halogen atom or a sulfonyloxy group.
- the target product can be obtained by allowing Z—Rd to act on the amino group of the raw material.
- R d is a chlorine atom, a bromine atom, an iodine atom, a methanesulfonyloxy group, a p-toluenesulfonyloxy group, or the like
- the reaction can be carried out with an amino form as a raw material in the presence of a suitable base.
- the base to be added include: Examples thereof include amines such as triethylamine and disopropylethylamine, and inorganic bases such as lithium carbonate.
- the reaction solvent include N, N-dimethylformamide, tetrahydrofuran, dioxane and the like. The reaction can be performed at O to 100 ° C.
- the reaction can be carried out under conditions using a primary amino group as a raw material and an appropriate reduction method.
- the reduction method used include a reducing agent such as sodium borohydride and sodium cyanoborohydride, and hydrogenation using palladium.
- a solvent to be used a solvent that does not participate in the reaction, such as ethanol, methanol, tetrahydrofuran, dioxane, and water can be used.
- the reaction can be carried out at a temperature between 20 and 100 ° C.
- It can be produced by converting an aminocarbonyl group into a cyano group by a general dehydration reaction.
- An example of this is a method using trifluoroacetic anhydride.
- the solvent to be used include solvents that do not participate in the reaction such as dichloromethane, chloroform, 1,2-dichloroethane, tetrahydrofuran, dioxane, and N, N-dimethylformamide.
- a base such as triethylamine, diisopropylethylamine, sodium hydrogencarbonate or potassium carbonate can be added.
- the reaction can be performed at -50 to 50 ° C.
- Another example is a method using phosphorus oxychloride.
- dichloromethane, chloroform, 1,2-dichloroethane, tetrahydrofuran, dioxane, pyridine and the like can be used alone or as a mixture of two or more kinds as solvents.
- imidazole and the like may be added. This reaction can be carried out at a temperature of 50-50 ° C.
- the fluorination method include a method using methylaminosulfur trifluoride / dimethylsulfur trifluoride or the like.
- the reaction is started at a temperature of from 78 ° C to room temperature using a solvent that does not participate in the reaction, such as tetrahydrofuran, dioxane, dichloromethane, chloroform, 1,2-dichloroethane, and toluene. Achieved by continuous reaction.
- fluorination is a method of converting a hydroxyl group into a leaving group and then converting it into a fluoro group. Conversion to a leaving group can be carried out in the same manner as described in Scheme 6.
- a method of converting to a fluoro group after converting to a leaving group a method of reacting tetrabutylammonium fluoride, cesium fluoride or the like can be mentioned. These reactions can be carried out using a solvent that does not participate in the reaction, such as tetrahydrofuran, dioxane, dichloromethane, chloroform, N, N-dimethylformamide, and water.
- Reaction formula 1 2 Reaction formula 1 2
- an amide or Amides or olebamates can be produced.
- the amidation reaction uses acyl octyl chloride, such as acyl chloride,
- the reaction can be performed in a solvent that does not participate in the reaction, such as chloroform, 1,2-dichloroethane, tetrahydrofuran, dioxane, toluene, and ethyl acetate.
- the reaction can be performed using a base.
- the base include amines such as triethylamine and diisopropylethylamine, sodium 2-ethylhexanoate, and 2-ethylhexanoic acid rim.
- Inorganic bases such as organic acid salts and carbonated lime are mentioned. These reactions can be performed at —50-100 ° C.
- the reaction can be carried out using an active ester such as 1-benzotriazolyl ester or succinimidyl ester.
- active ester such as 1-benzotriazolyl ester or succinimidyl ester.
- the reaction solvent include dichloromethane, chloroform, 1,2-dichloroethane, N, N-dimethylformamide, tetrahydrofuran, dioxane, toluene, and ethyl acetate.
- the reaction can be performed at -50 to 50 ° C.
- amidation can be performed using a carboxylic acid and a dehydrating condensing agent.
- the dehydrating condensing agent include 1-ethyl-3- (3-dimethylaminopropyl) carbodiimide hydrochloride, dicyclohexyl carbodiimide, diphenylphosphoryl azide, and lipoeldiimidazole.
- Activators such as 1-hydroxybenzotriazole and hydroxysuccinimide can be used accordingly.
- reaction solvent examples include dichloromethane, chloroform, 1,2-dichloroethane, N, N-dimethylformamide, tetrahydrofuran, dioxane, toluene, and ethyl acetate.
- the reaction can be carried out using a base.
- the base include amines such as triethylamine and diisopropylethylamine, sodium salts such as sodium 2-ethylhexanoate, and organic acid salts such as sodium 2-hexylhexanoate, And inorganic bases such as potassium carbonate.
- the reaction can be carried out at a temperature of 50 to 50 ° C.
- amidation can be performed using a mixed acid anhydride obtained from a carboxylic acid and chlorocarbonate.
- Solvents for these reactions include tetrahydrofuran, dioxane, dichloromethane, chloroform, N, N-dimethylform. Solvents that do not participate in the reaction, such as muamide, toluene, and ethyl acetate.
- the reaction can be carried out using a base.
- the base include amines such as triethylamine and diisopropylethylamine, sodium 2-ethylhexanoate, and 2-ethylhexanoic acid rim.
- Inorganic bases such as organic acid salts and carbonated lime are mentioned. These reactions can be carried out at a temperature of 50 to 50 ° C.
- the protection of the amino group can be carried out using di-tert-butyldicarboxylate, benzyloxycarboechloride, fluorenylmethoxycarbonyl chloride or the like in the presence of a suitable base.
- the base include amines such as triethylamine and diisopropylethylamine, and inorganic bases such as carbonated lime.
- Solvents for these reactions include solvents that do not participate in the reaction, such as tetrahydrofuran, dioxane, dichloromethane, chloroform, N, N-dimethylformamide, toluene, ethyl acetate, and water. These reactions can be carried out at a temperature of from 50 to 50 ° C. ⁇ , Equation 1 3
- R Re is the same as described above.
- R f represents a hydrogen atom or a lower alkyl group, a benzyl group, an aryl group, or the like.
- a compound in which COOR f is a carbonyl group or a salt thereof is used as a raw material, synthesis can be performed using ammonia under general amidation conditions.
- amidation there is a method in which a carboxyl group or a salt thereof is converted to an acid chloride using thionyl chloride, phosphorus oxychloride, oxalyl chloride or the like, and then condensed with ammonia.
- Solvents for these reactions include Solvents that do not participate in the reaction include butane, dioxane, dichloromethane, chloroform, 1,2-dichloroethane, N, N-dimethylformamide, toluene, and ethyl acetate. These reactions can be performed at -50 to 50 ° C.
- Another example is amidation using a dehydrating condensing agent and ammonia.
- a reaction using a condensing agent such as 11-ethyl-3- (3-dimethylaminopropyl) carbodiimide hydrochloride, dicyclohexyl carbodiimide, diphenylphosphoryl azide, carboxydiimidazole, etc.
- Activators such as 1-hydroxybenzotriazole and hydroxysuccinimide can be added.
- Solvents for these reactions include solvents that do not participate in the reaction, such as tetrahydrofuran, dioxane, dichloromethane, chloroform, 1,2-dichloroethane, N, N-dimethylformamide, toluene, ethyl acetate, and acetonitrile. . These reactions can be carried out at a temperature of 50 to 50 ° C.
- amidation can be carried out using ammonia and a mixed acid anhydride obtained from carboxylic acid and chlorocarbonate.
- Solvents for these reactions include solvents that do not participate in the reaction, such as tetrahydrofuran, dioxane, dichloromethane, chloroform, 1,2-dichloroethane, N, N-dimethylformamide, toluene, and ethyl acetate. These reactions can be performed at —50-50 ° C.
- the conversion of a compound in which COOR ⁇ is an ester to an aminocarbonyl group can be carried out by directly reacting with ammonia, or can be once converted to a carboxylic acid or a salt thereof and then converted to an aminocarbonyl group by the above method. it can.
- a method for converting an ester to a carboxylic acid or a salt thereof the method described in PROTECTIVE GROUPS IN ORGAN IC SYNTHESIS, THEODORA W. GREENE and PETER GM WU TS can be used.
- the reaction of direct conversion with ammonia uses ammonia gas or ammonia water in a solvent such as water, methanol, ethanol, tetrahydrofuran, dioxane, dichloromethane, chloroform, N, N-dimethylformamide, or toluene, or without solvent.
- a solvent such as water, methanol, ethanol, tetrahydrofuran, dioxane, dichloromethane, chloroform, N, N-dimethylformamide, or toluene, or without solvent.
- O can be performed in a temperature range of 100 ° C. In some cases, it can be carried out in a sealed system to prevent the volatilization of ammonia.
- Rb which is a protecting group for an amino group
- Rb can be deprotected by, for example, the method described in Reaction Scheme 3.
- the resulting amine can be removed as a base or as a salt of a suitable acid.
- suitable acids include, for example, hydrochloric acid, sulfuric acid, trifluoroacetic acid, p-toluenesulfonic acid, methanesulfonic acid, acetic acid and the like.
- (2S, 4S) -1-1 (tert-butylamino) acetyl-2-cyano-14-fluoropyrrolidine (0.26g) ).
- This part (0.25 g) was added to an ice-cooled getyl ether solution of 4 M hydrochloric acid (ethyl acetate solution, 0.3 mL), and the mixture was stirred at room temperature for 1 hour. The insolubles were collected by filtration to give the title compound (0.28 g) as a colorless powder.
- Dipeptidyl peptidase IV (DPP IV) activity inhibition experiments were performed according to the method described in Diabetes, 47, 764-769, 1998.
- Plasma containing dipeptidyl peptidase IV was prepared by collecting blood from healthy volunteers and centrifuging. The enzymatic reaction was carried out using a 96-well flat bottom plate in a buffer consisting of 25 mM HEPES, 14 OmM NaC 1% BSA, pH 7.8.
- the reaction was stopped by adding 50 1 of 25% acetic acid aqueous solution.
- the amount of the released 7-amino-4-methylcoumarin was measured at 460 nm when excited at 390 nm using a fluorescence plate reader (1420 ARVOTM Multi-absorber; Wa11ac).
- the fluorescence intensity when the reaction time was set to 0 minutes after the addition of the solvent was defined as a blank value, and the value obtained by subtracting the blank value from each measured value was defined as the specific fluorescence intensity. From the obtained specific fluorescence intensity, the inhibition rate (%) of dipeptidyl peptidase IV activity was determined by the following equation.
- the test compound was prepared by preparing a dimethylsulfoxide solution having a 1000-fold higher concentration, and diluting it with the above buffer. From the inhibition rate at each concentration, the concentration of the compound showing 50% inhibition ( IC5Q value) was calculated. As a result, the compound of Reference Example 1 exhibited an excellent DPPIV inhibitory activity with an IC 50 of 0.6 nM.
- OGTT in Zucker fatty rats was carried out with reference to the method described in Diabetologia, 42, 1324-1331, 1999.
- 10-week-old male Zucker fatty rats (Nippon Charus Riva) were used after a 16-hour fast. Water was taken freely until immediately before use, and thereafter water was cut off until the end of the test. Blood was collected via heparin-treated blood collection tube (Drummond Scientific) before the start of the test; blood was collected from the fundus vein. The test compound was orally administered as a solution.
- Sugar was dissolved in water for injection in the Japanese Pharmacopoeia and administered orally as a sugar at a dose of 1 g / kg body weight or 2 gZkg body weight 15 or 30 minutes after administration of the test compound and water for injection.
- Blood was collected from the fundus vein at 15, 30 and 60 minutes after glucose administration.
- the blood sample was immediately mixed with heparin (manufactured by Shimizu Pharmaceutical), centrifuged at 3000 rpm for 15 minutes at 4 ° C, and the plasma was collected and immediately frozen.
- the blood glucose level (mg / dl) of the frozen sample was measured with a glucose CII test II (manufactured by Wako Pure Chemical Industries, Ltd.) and the area under the curve (min * mgZd 1) was calculated. (However, the blood glucose level of the sample obtained by blood collection before the test was started was used as the 0-minute blood glucose level.)
- the compounds of the examples suppressed an increase in blood glucose level.
- DPPIV dipeptidyl peptidase IV
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Diabetes (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2003235913A AU2003235913A1 (en) | 2002-05-09 | 2003-05-09 | Cyanopyrrolidine derivatives |
JP2004508532A JPWO2003095425A1 (ja) | 2002-05-09 | 2003-05-09 | シアノピロリジン誘導体 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2002-134421 | 2002-05-09 | ||
JP2002134421 | 2002-05-09 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2003095425A1 true WO2003095425A1 (fr) | 2003-11-20 |
Family
ID=29416708
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2003/005813 WO2003095425A1 (fr) | 2002-05-09 | 2003-05-09 | Derives de cyanopyrrolidine |
Country Status (3)
Country | Link |
---|---|
JP (1) | JPWO2003095425A1 (fr) |
AU (1) | AU2003235913A1 (fr) |
WO (1) | WO2003095425A1 (fr) |
Cited By (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004101514A1 (fr) * | 2003-05-15 | 2004-11-25 | Taisho Pharmaceutical Co., Ltd. | Derive du type cyanofluoropyrrolidine |
WO2007102286A1 (fr) | 2006-03-08 | 2007-09-13 | Kyorin Pharmaceutical Co., Ltd. | Procede de production d'un derive aminoacetylpyrrolidinecarbonitrile et intermediaire utilise pour sa production |
WO2007120702A2 (fr) | 2006-04-11 | 2007-10-25 | Arena Pharmaceuticals, Inc. | Agonistes du récepteur de gpr119 dans des procédés d'augmentation de la masse osseuse et de traitement de l'ostéoporose et autres états se caractérisant par une masse osseuse faible, et thérapie de combinaison associée |
US7291618B2 (en) | 2004-05-12 | 2007-11-06 | Pfizer Inc | Therapeutic compounds |
WO2008114857A1 (fr) | 2007-03-22 | 2008-09-25 | Kyorin Pharmaceutical Co., Ltd. | Procédé de préparation d'un dérivé d'aminoacétylpyrrolidinecarbonitrile |
EP2116235A1 (fr) | 2005-01-10 | 2009-11-11 | Arena Pharmaceuticals, Inc. | Thérapie combinée pour le traitement des diabètes et des conditions associées, et pour le traitement des conditions améliorées par l'augmentation du niveau de sang GLP-1 |
US7754757B2 (en) | 2004-02-05 | 2010-07-13 | Kyorin Pharmaceutical Co., Ltd. | Bicycloester derivative |
WO2011005929A1 (fr) | 2009-07-09 | 2011-01-13 | Arena Pharmaceuticals, Inc. | Dérivé de pipéridine et son utilisation pour le traitement du diabète et de l'obésité |
WO2011127051A1 (fr) | 2010-04-06 | 2011-10-13 | Arena Pharmaceuticals, Inc. | Modulateurs du récepteur de gpr119 et traitement de troubles associés |
WO2012040279A1 (fr) | 2010-09-22 | 2012-03-29 | Arena Pharmaceuticals, Inc. | Modulateurs du récepteur gpr119 et traitement des troubles qui lui sont liés |
WO2012135570A1 (fr) | 2011-04-01 | 2012-10-04 | Arena Pharmaceuticals, Inc. | Modulateurs du récepteur gpr119 et traitement de troubles qui lui sont associés |
WO2012145603A1 (fr) | 2011-04-22 | 2012-10-26 | Arena Pharmaceuticals, Inc. | Modulateurs du récepteur gpr119 et traitement de troubles liés à celui-ci |
WO2012145361A1 (fr) | 2011-04-19 | 2012-10-26 | Arena Pharmaceuticals, Inc. | Modulateurs du récepteur gpr119 et traitement de troubles liés à celui-ci |
WO2012145604A1 (fr) | 2011-04-22 | 2012-10-26 | Arena Pharmaceuticals, Inc. | Modulateurs du récepteur gpr119 et traitement de troubles liés à celui-ci |
WO2012170702A1 (fr) | 2011-06-08 | 2012-12-13 | Arena Pharmaceuticals, Inc. | Modulateurs du récepteur gpr119 et traitement de troubles associés à celui-ci |
WO2013055910A1 (fr) | 2011-10-12 | 2013-04-18 | Arena Pharmaceuticals, Inc. | Modulateurs du récepteur gpr119 et traitement de troubles associés |
WO2014074668A1 (fr) | 2012-11-08 | 2014-05-15 | Arena Pharmaceuticals, Inc. | Modulateurs de gpr119 et traitement de troubles associés à ceux-ci |
US8883714B2 (en) | 2008-04-07 | 2014-11-11 | Arena Pharmaceuticals, Inc. | Pharmaceutical compositions comprising GPR119 agonists which act as peptide YY (PYY) secretagogues |
US10555929B2 (en) | 2015-03-09 | 2020-02-11 | Coherus Biosciences, Inc. | Methods for the treatment of nonalcoholic fatty liver disease and/or lipodystrophy |
US11253508B2 (en) | 2017-04-03 | 2022-02-22 | Coherus Biosciences, Inc. | PPARy agonist for treatment of progressive supranuclear palsy |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2000511559A (ja) * | 1996-11-07 | 2000-09-05 | ノバルティス アクチエンゲゼルシャフト | N―置換2―シアノピロリジン |
WO2002038541A1 (fr) * | 2000-11-10 | 2002-05-16 | Taisho Pharmaceutical Co., Ltd. | Derives de cyanopyrrolidine |
WO2003002553A2 (fr) * | 2001-06-27 | 2003-01-09 | Smithkline Beecham Corporation | Fluoropyrrolidines inhibitrices de la dipeptidyl peptidase |
WO2003002531A2 (fr) * | 2001-06-27 | 2003-01-09 | Smithkline Beecham Corporation | Fluoropyrrolidines inhibitrices de la dipeptidyl peptidase |
-
2003
- 2003-05-09 JP JP2004508532A patent/JPWO2003095425A1/ja not_active Withdrawn
- 2003-05-09 AU AU2003235913A patent/AU2003235913A1/en not_active Abandoned
- 2003-05-09 WO PCT/JP2003/005813 patent/WO2003095425A1/fr active Application Filing
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2000511559A (ja) * | 1996-11-07 | 2000-09-05 | ノバルティス アクチエンゲゼルシャフト | N―置換2―シアノピロリジン |
WO2002038541A1 (fr) * | 2000-11-10 | 2002-05-16 | Taisho Pharmaceutical Co., Ltd. | Derives de cyanopyrrolidine |
WO2003002553A2 (fr) * | 2001-06-27 | 2003-01-09 | Smithkline Beecham Corporation | Fluoropyrrolidines inhibitrices de la dipeptidyl peptidase |
WO2003002531A2 (fr) * | 2001-06-27 | 2003-01-09 | Smithkline Beecham Corporation | Fluoropyrrolidines inhibitrices de la dipeptidyl peptidase |
Cited By (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004101514A1 (fr) * | 2003-05-15 | 2004-11-25 | Taisho Pharmaceutical Co., Ltd. | Derive du type cyanofluoropyrrolidine |
US8053465B2 (en) | 2004-02-05 | 2011-11-08 | Kyorin Pharmaceutical Co., Ltd. | Bicycloester derivative |
US7754757B2 (en) | 2004-02-05 | 2010-07-13 | Kyorin Pharmaceutical Co., Ltd. | Bicycloester derivative |
US7291618B2 (en) | 2004-05-12 | 2007-11-06 | Pfizer Inc | Therapeutic compounds |
US7465732B2 (en) | 2004-05-12 | 2008-12-16 | Pfizer Inc | (2S,4S)-4-(piperazin-1-yl)pyrrolidine-2-methanone derivatives |
EP2116235A1 (fr) | 2005-01-10 | 2009-11-11 | Arena Pharmaceuticals, Inc. | Thérapie combinée pour le traitement des diabètes et des conditions associées, et pour le traitement des conditions améliorées par l'augmentation du niveau de sang GLP-1 |
JP5101489B2 (ja) * | 2006-03-08 | 2012-12-19 | 杏林製薬株式会社 | アミノアセチルピロリジンカルボニトリル誘導体の製造方法およびその製造中間体 |
WO2007102286A1 (fr) | 2006-03-08 | 2007-09-13 | Kyorin Pharmaceutical Co., Ltd. | Procede de production d'un derive aminoacetylpyrrolidinecarbonitrile et intermediaire utilise pour sa production |
EP2253311A2 (fr) | 2006-04-11 | 2010-11-24 | Arena Pharmaceuticals, Inc. | Utilisation d'agonistes du récepteur de GPR119 dans des procédés d'augmentation de la masse osseuse et de traitement de l'ostéoporose, et thérapie de combinaison associée |
WO2007120702A2 (fr) | 2006-04-11 | 2007-10-25 | Arena Pharmaceuticals, Inc. | Agonistes du récepteur de gpr119 dans des procédés d'augmentation de la masse osseuse et de traitement de l'ostéoporose et autres états se caractérisant par une masse osseuse faible, et thérapie de combinaison associée |
WO2008114857A1 (fr) | 2007-03-22 | 2008-09-25 | Kyorin Pharmaceutical Co., Ltd. | Procédé de préparation d'un dérivé d'aminoacétylpyrrolidinecarbonitrile |
US8883714B2 (en) | 2008-04-07 | 2014-11-11 | Arena Pharmaceuticals, Inc. | Pharmaceutical compositions comprising GPR119 agonists which act as peptide YY (PYY) secretagogues |
WO2011005929A1 (fr) | 2009-07-09 | 2011-01-13 | Arena Pharmaceuticals, Inc. | Dérivé de pipéridine et son utilisation pour le traitement du diabète et de l'obésité |
WO2011127051A1 (fr) | 2010-04-06 | 2011-10-13 | Arena Pharmaceuticals, Inc. | Modulateurs du récepteur de gpr119 et traitement de troubles associés |
EP3323818A1 (fr) | 2010-09-22 | 2018-05-23 | Arena Pharmaceuticals, Inc. | Modulateurs du récepteur gpr119 et traitement de troubles associés |
WO2012040279A1 (fr) | 2010-09-22 | 2012-03-29 | Arena Pharmaceuticals, Inc. | Modulateurs du récepteur gpr119 et traitement des troubles qui lui sont liés |
WO2012135570A1 (fr) | 2011-04-01 | 2012-10-04 | Arena Pharmaceuticals, Inc. | Modulateurs du récepteur gpr119 et traitement de troubles qui lui sont associés |
WO2012145361A1 (fr) | 2011-04-19 | 2012-10-26 | Arena Pharmaceuticals, Inc. | Modulateurs du récepteur gpr119 et traitement de troubles liés à celui-ci |
WO2012145604A1 (fr) | 2011-04-22 | 2012-10-26 | Arena Pharmaceuticals, Inc. | Modulateurs du récepteur gpr119 et traitement de troubles liés à celui-ci |
WO2012145603A1 (fr) | 2011-04-22 | 2012-10-26 | Arena Pharmaceuticals, Inc. | Modulateurs du récepteur gpr119 et traitement de troubles liés à celui-ci |
WO2012170702A1 (fr) | 2011-06-08 | 2012-12-13 | Arena Pharmaceuticals, Inc. | Modulateurs du récepteur gpr119 et traitement de troubles associés à celui-ci |
WO2013055910A1 (fr) | 2011-10-12 | 2013-04-18 | Arena Pharmaceuticals, Inc. | Modulateurs du récepteur gpr119 et traitement de troubles associés |
WO2014074668A1 (fr) | 2012-11-08 | 2014-05-15 | Arena Pharmaceuticals, Inc. | Modulateurs de gpr119 et traitement de troubles associés à ceux-ci |
US10555929B2 (en) | 2015-03-09 | 2020-02-11 | Coherus Biosciences, Inc. | Methods for the treatment of nonalcoholic fatty liver disease and/or lipodystrophy |
US10772865B2 (en) | 2015-03-09 | 2020-09-15 | Coherus Biosciences, Inc. | Methods for the treatment of nonalcoholic fatty liver disease and/or lipodystrophy |
US11400072B2 (en) | 2015-03-09 | 2022-08-02 | Coherus Biosciences, Inc. | Methods for the treatment of nonalcoholic fatty liver disease and/or lipodystrophy |
US11253508B2 (en) | 2017-04-03 | 2022-02-22 | Coherus Biosciences, Inc. | PPARy agonist for treatment of progressive supranuclear palsy |
Also Published As
Publication number | Publication date |
---|---|
AU2003235913A1 (en) | 2003-11-11 |
JPWO2003095425A1 (ja) | 2005-09-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP3987890B2 (ja) | シアノピロリジン誘導体 | |
WO2003095425A1 (fr) | Derives de cyanopyrrolidine | |
JP2004026820A (ja) | ジペプチジルペプチダーゼiv阻害剤 | |
US9469609B2 (en) | Synthesis of pyrrolidine compounds | |
EP1361212A1 (fr) | Dérivés peptidiques comme agents antithrombotiques | |
CN1173872A (zh) | 凝血酶抑制剂 | |
JP2002265439A (ja) | シアノピロリジン誘導体およびその医薬用途 | |
ES2409062T3 (es) | Derivados de indolinona sustituidos en posición 6, su preparación y su uso como medicamentos | |
JP2005139107A (ja) | ジペプチジルペプチダーゼiv阻害剤 | |
JP2006516557A (ja) | プロリルオリゴペプチダーゼ阻害活性を有する化合物 | |
US20040220253A1 (en) | Synthesis of pyrrole amides | |
CA2512476A1 (fr) | Derivees de cyanopyrrolidine | |
ZA200302591B (en) | Cyanopyrrolidine derivatives. | |
AU2006246479A1 (en) | Cyanopyrrolidine derivatives | |
JP2002534425A (ja) | マトリックスメタロプロテイナーゼ阻害剤として有用な3−(チオ置換アミド)−ラクタム類 | |
CA2356966A1 (fr) | Amidomalonamides et leurs utilisations comme inhibiteurs des metalloproteinases matricielles |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2004508532 Country of ref document: JP |
|
122 | Ep: pct application non-entry in european phase |